Potentiation of the uterus-relaxing effects of B-adrenergic agonists with nifedipine: studies on rats and the human myometrium. by Hajagos-Tóth, Judit et al.
Acta Obstetricia et Gynecologica. 2010; 89: 1284–1289
MAIN RESEARCH ARTICLE
Potentiation of the uterus-relaxing effects of b-adrenergic agonists with
nifedipine: studies on rats and the human myometrium
JUDIT HAJAGOS-TÓTH1, ZSOLT KORMÁNYOS2, GEORGE FALKAY1, ATTILA PÁL2 &
RÓBERT GÁSPÁR1
1Department of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Szeged, Hungary,
and 2Department of Obstetrics and Gynecology, Albert Szent-Györgyi Clinical Center, Faculty of General Medicine,
University of Szeged, Szeged, Hungary
Abstract
Objective.We investigated how progesterone and salmeterol modify the effect of nifedipine in an in vivo preterm birth model in
rats, and how terbutaline and nifedipine modify the contractions of the isolated human myometrium. Design. Experimental
animal and human myometrial studies. Sample. Twenty-four female Sprague–Dawley rats and 13 human uterine tissues
sampled from cesarean section. Methods. Preterm birth was induced in Sprague–Dawley rats with a combination of
mifepristone and prostaglandin-E2. The animals were treated with nifedipine or its combination with salmeterol and
progesterone. Additionally, isolated human myometrial strips from cesarean sections were stimulated with oxytocin, and
the inhibitory effects of nifedipine and terbutaline were studied. Results.Nifedipine delayed the preterm delivery in the rats, but
its effect was tripled by the addition of b2-mimetics, or abolished after progesterone pretreatment. Synergism was observed in
the relaxing effects of nifedipine and terbutaline on the isolated human myometrium. Conclusion. The action of nifedipine in
delaying labor is impeded by progesterone. A combination of nifedipine and b2-agonists should be considered for the treatment
or prevention of preterm birth.
Key words: b2-Mimetics, nifedipine, preterm, progesterone
Introduction
Preterm birth is the major cause of perinatal mortality
and morbidity in the developed world. With a view to
decreasing the potential maternal and fetal adverse
events and improving the perinatal outcome, there is
growing interest in experimental studies of the pos-
sible use of different tocolytic combinations (1,2).
The most important factor governing the force of
myometrial contractility is dependent not only on Ca2+
entry but also on the propagation of electrical signals
over the uterus to recruit additional cells. In the
myometrium, the membrane potential is the major
factor inﬂuencing the entry of Ca2+ into the cells via
the L-type Ca2+ channels. Dihydropyridine antago-
nists such as nifedipine exert their effects by binding
to L-type channels; they act by abolishing trans-
membrane calcium inﬂux, and impede the increase
in intracellular Ca2+ necessary for activation of the
contractile proteins. Among the Ca2+ entry blockers,
the dihydropyridines are the most potent and selective
inhibitors of uterine tension development, and have
been used as tocolytics to prevent preterm labor for
more than 20 years (3–5).
The activity of L-type Ca2+ channels is regulated by
several factors (6). b-Adrenergic stimulants are
known to produce smooth muscle cell relaxation by
raising the intracellular level of cyclic AMP, which
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activates protein kinase A. This activated form leads
to phosphorylation of the Ca2+ channels. This mech-
anism in the heart muscle (7) might be similar to that
in the pregnant myometrium. Investigation of the
effects of combination of b2-agonists and Ca2+ chan-
nel blockers in the isolated trachea has demonstrated
that both isradipine and nifedipine potentiated the
relaxant action of terbutaline and salmeterol, respec-
tively (8). We earlier reported (9) that the addition of a
b2-agonist to a Ca2+ channel blocker enhanced the
effect of the Ca2+ antagonist on the isolated pregnant
rat myometrium, although the extent of potentiation
depended on the sequence of administration of the
two compounds. The efﬁcacy of this combination has
neither been investigated in vivo nor tested in human
uterine tissue.
Another factor which regulates the L-type Ca2+
channel is the progesterone/estrogen ratio. Helguera
et al. (10) established that the uterine smooth muscle
possesses a1C-long and a1C-short Ca2+ channels iso-
forms. Progesterone favors the expression of the long
form, in the presence of which the channel has lower
activity. We found (9) that progesterone pretreatment
decreased the inhibitory effect of nifedipine in the
isolated rat myometrium, but there have been no
studies to conﬁrm this in vivo.
Our aims in the present study were to learn whether
the administration of nifedipine or a nifedipine–b2-
agonist combination can delay preterm birth, whether
this latter combination inﬂuences the contractions of
the isolated human myometrium, and whether pro-
gesterone treatment decreases the effects of nifedi-
pine in hormone-induced preterm delivery in rats
in vivo.
Material and methods
Animal studies
The animals were treated in accordance with the
European Communities Council Directives (86/609/
ECC) and the Hungarian Act for the Protection of
Animals in Research (XXVIII.tv.32.§). All experi-
ments involving animal subjects were carried out
with the approval of the Hungarian Ethical Commit-
tee for Animal Research (registration number: IV/
1758-2/2008). Sprague–Dawley rats (Charles River
Laboratories, Hungary) were kept at 22 ± 3C; the
relative humidity was 30–70% and the light/dark cycle
was 12 hours/12 hours. They were maintained on a
standard rodent pellet diet (Charles River Laborato-
ries), with tap water available ad libidum.
Mature female (180–200 g) and male (240–260 g)
Sprague–Dawley rats were mated in a special mating
cage. Vaginal smears were taken from the female rats
and a sperm search was performed under a micro-
scope at a magniﬁcation of 1200. If the smear
proved positive, the female rats were separated and
were regarded as ﬁrst-day pregnant animals.
Preterm labor was induced according to
Rechberger et al. (11). Brieﬂy, the animals were
treated with mifepristone (3 mg per 0.1 ml) (donated
by Richter Gedeon NyRt, Budapest, Hungary) and
prostaglandin-E2 (PGE2; 0.5 mg/animal) (Sigma–
Aldrich, Budapest, Hungary) on day 19 of pregnancy,
considered that the duration of pregnancy is 22 days
in the rat. Mifepristone was suspended in olive oil
(Sigma–Aldrich, Budapest, Hungary) and adminis-
tered as a subcutaneous injection at 9:00 am. At
4:00 pm, PGE2 was applied intravaginally. The deliv-
ery time of the ﬁrst fetus was noted as the duration in
hours from the time of mifepristone administration.
Nifedipine (Sigma–Aldrich, Budapest, Hungary)
was dissolved in a 6:6:4 polyethylene glycol (Sigma–
Aldrich, Budapest, Hungary), ethanol (Sigma–Aldrich,
Budapest, Hungary) and physiologic saline mix-
ture. Salmeterol xinafoate (Sigma–Aldrich, Budapest,
Hungary) was dissolved in a 1:1 methanol (Sigma–
Aldrich, Budapest, Hungary) and water mixture.
Alzet osmotic pumps (model 2ml1; DURECT
Corp., Cupertino, CA) were loaded with nifedipine,
salmeterol xinofoate solution or vehicle. In the com-
bination studies, two separate osmotic pumps were
inserted subcutaneously into the back skin of the rats
on day 16 or 18 of pregnancy (which may correlate to
gestation weeks 30–35 in humans) under isoﬂurane
anesthesia (Burton’s narcotic apparatus). The dose of
nifedipine was 3.89 mg/day per animal and that of
salmeterol xinofoate was 0.13 mg/day per animal.
The progesterone (Sigma–Aldrich, Budapest,
Hungary) treatment was started on day 15 of
pregnancy. Progesterone was dissolved in corn oil
(Sigma–Aldrich, Budapest, Hungary) and injected
subcutaneously daily until delivery (day 19 or 20)
in a dose of 0.5 mg/0.1 ml.
Group A was the control group, while group B was
treated with vehicle, group C with nifedipine, group D
with the nifedipine–salmeterol combination and
group E with the nifedipine–progesterone combina-
tion. There were eight rats in each group.
Human myometrial studies
Biopsy specimens of human myometrial tissue were
obtained at cesarean section in the third trimester of
pregnancy. Uterine smooth muscle tissue samples
were collected at 37–40 weeks of gestation from
13 women who were underwent cesarean delivery
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because of fetal distress, growth restriction, a previous
cesarean delivery, breech presentation, or suspected
cephalopelvic disproportion. None of the women was
treated with any tocolytic agent. The parity of the
women varied from 0 to 3, and their mean age was
29.7 years, range 26–37 years. In all cases, the oper-
ation was performed under spinal anesthesia. The
Ethical Committee of Albert Szent-Györgyi Clinical
Center approved the clinical protocol for the use of
human tissue from fully informed and consenting
women (registration number: 114/2009). Each tissue
sample (10  10  20 mm) was obtained from the
upper edge of a lower-segment transverse incision,
after delivery of the child, but before oxytocin was
given to the mother. Tissues were stored in Krebs–
Henseleit solution at 4C, and were used within
12 hours of collection.
Longitudinal myometrial strips (measuring approx-
imately 3 5 10 mm) were mounted vertically in an
organ bath containing 10 ml Krebs–Henseleit (com-
position: 118 mM sodium chloride, 5 mM potassium
chloride, 2 mM calcium chloride, 0.5 mM magne-
sium sulfate, 1 mM potassium sulfate, 25 mM sodium
bicarbonate, 10 mM glucose; pH 7.4) solution. The
organ bath was maintained at 37C and carbogen
(95% O2 + 5% CO2) was bubbled through it. After
mounting, the rings were equilibrated for ~2 hours
before experiments were undertaken, with a solution
change every 15 minutes.
We searched for the optimum initial tension. The
best response appeared with a pretension of 2–3 g. In
order to maintain adequate tension even after higher
spontaneous relaxation, the initial tension of the
preparation was set to ~3.00 g, which was relaxed
to ~1.5 g at the end of equilibration.
The tension of the myometrial rings was measured
with an isometric force transducer (SG-02; Experi-
metria Ltd., Budapest, Hungary) and recorded with a
SPEL Advanced ISOSYS Data Acquisition System
(Experimetria Ltd., Budapest, Hungary).
The ﬁrst responses of the strips to 106 M oxytocin
were analyzed at the beginning of the experiments.
No differences were found between contractility of
the myometrial strips suggesting that pharmacolog-
ical sensitivities of the samples were very similar. In
each experiment, an untreated control preparation
was included to measure the relaxation caused by
spontaneous relaxation of the tissues. After eliciting
contractions with 106 M oxytocin, non-cumulative
dose–response curves were constructed for each
experiment with nifedipine (1011–105 M) and
terbutaline (Sigma–Aldrich, Budapest, Hungary)
(107 M) or terbutaline (1011–105 M) and nifed-
ipine (107 M). Drugs were used from stock solu-
tions and stored at 20C.
Statistical analysis
In the animal studies, statistical analyses were carried
out through the analysis of Dunnett’s Multiple Com-
parison Test.
In the human myometrial studies, concentration–
response curves were ﬁtted, and area under curves
(AUCs) were evaluated and analyzed with the Prism
4.0 (Graphpad Software Inc., San Diego, CA, USA)
computer program. In all experiments an untreated
control preparation was included to ensure that no
spontaneous decrease in contractile activity occurred
during the experimental period. The maximal inhib-
itory effect (Emax) and EC50 values in the curves
obtained with the combinations were calculated.
For statistical evaluations, data were analyzed by
the unpaired t-test.
Results
In vivo studies
In group A (control), preterm labor occurred
within 24 hours after mifepristone treatment, at about
9:00 am on pregnancy day 20. The vehicle (group B)
did not alter the time of delivery relative to that in
group A.
Nifedipine (group C) treatment started on preg-
nancy day 16 was effective in delaying the hormone-
induced preterm delivery by 6.6 hours. In group D
(nifedipine–salmeterol combination), the treatment
was extremely effective; preterm birth was delayed
by ~24 hours as compared with group A (Figure 1).
When started on day 18 of pregnancy (Figure 2),
nifedipine treatment (group C) was not effective. By
contrast, in group D (combination therapy) the treat-
ment was effective; labor was delayed by ~25 hours.
The difference in efﬁcacy between groups C and D
was most expressed for the treatment started on
day 18.
With the nifedipine–progesterone combination
(Figure 3), the progesterone pretreatment (group E)
abolished the effect of nifedipine (group C).
Organ bath studies
The 106 M oxytocin-stimulated human uterine con-
tractions were inhibited concentration-dependently by
nifedipine and terbutaline in the range 1011105 M
(Figure 4A,B). The addition of 107 M terbutaline to
nifedipine did not alter the Emax of nifedipine, but
increased EC50 from 1.8  108 M to 1.5  106 M
(p < 0.05) (Figure 4A). The addition of 107 M
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nifedipine to terbutaline increased the Emax of terbu-
taline (Figure 4B), from 60.8 to 76.8% (p < 0.01) but
EC50 was not changed. Interestingly, nifedipine was
able to enhance the relaxing effect of terbutaline to a
signiﬁcant level even at the concentration of 1011 M.
Discussion
Combinations of different uterine relaxing agents
should be considered as a possibility to enhance the
efﬁcacy of tocolytic therapy. The effect of combined
salmeterol–gestagen treatment in hormone-induced
preterm delivery in rats in vivo was investigated earlier
(2): salmeterol treatment started on pregnancy day 16
delayed preterm birth by 2.8 hours and the salmeterol–
progesterone combination caused a 4.5-hour delay.
Those results led us to test the efﬁcacy of nifedipine–
salmeterol and nifedipine–progesterone combination
treatment in hormone-induced preterm delivery
in rat in vivo. Preterm delivery was induced by
the deprivation of progesterone using progesterone
antagonist combined with prostaglandin E2 to accel-
erate cervical ripening on pregnancy day 19. At this
stage of pregnancy the function of corpus luteum
declines which is mainly attributed to the luteolytic
effect of prostaglandin F2a (12). It is also known that
progesterone induces the metabolism of prostaglan-
dins, thus substitution of progesterone is anticipated
to improve relaxation response in late-pregnant rat
uterus (13).
We used the same in vivo salmeterol dose as it was
effective indelayingpretermbirth, and theprogesterone
dose that had increased the effect of salmeterol. The
in vivo dose for the tocolytic effect was calculated
by using the pharmacokinetic parameters reported
for nifedipine in pregnant rats by Downing and
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Figure 2. The effects of treatment with nifedipine (3.89 mg/day)
or the nifedipine–salmeterol combination on hormone-induced
preterm delivery in the rat (n = 8 for each group). Treatment
was started on gestation day 18. A: control group; B: vehicle-
treated (PEG400:ethanol:physiological salt solution = 6:6:4 +
methanol:water = 1:1 in osmotic minipump); C: nifedipine-treated;
D: nifedipine–salmeterol combination-treated animals. The bar
graphs show means ± SD. The effects were compared with the
results on group A. ns, not signiﬁcant. ***p < 0.001. The difference
in efﬁcacy between the treatments in group C and D was signiﬁcant
(p < 0.001).
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Figure 3. The effects of treatment with nifedipine (3.89 mg/day) or
the nifedipine–progesterone combination on hormone-induced
preterm delivery in the rat (n = 8 for each group). Treatments
were started on gestation day 16. A: control group; B: vehicle-
treated (PEG400:ethanol:physiological salt solution = 6:6:4
in osmotic minipump + corn oil s.c.); C: nifedipine-treated;
D: nifedipine–progesterone combination-treated animals. The
bar graphs show means ± SD. The effects were compared with
the results on group A. ns, not signiﬁcant. ***p < 0.001. The
difference in efﬁcacy between the treatments in group C and D
was signiﬁcant (p < 0.001).
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Figure 1. The effects of treatment with nifedipine (3.89 mg/day) or
the nifedipine–salmeterol combination on hormone-induced pre-
term delivery in the rat (n = 8 for each group). Treatment was
started on gestation day 16. A: control group; B: vehicle-treated
(PEG400:ethanol:physiological salt solution = 6:6:4 + methanol:
water = 1:1 in osmotic minipump); C: nifedipine-treated; D: nifed-
ipine–salmeterol combination-treated animals. The bar graphs show
means ± SD. The effects were compared with the results on group
A. ns, not signiﬁcant. *p < 0.05; ***p < 0.001. The difference in
efﬁcacy between the treatments in groups C and D was signiﬁcant
(p < 0.001).
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Hollingsworth (14). We planned the administration of
a dose regimen via osmotic pumps which provided a
plasma nifedipine concentration of ~1.5 mg/ml (esti-
mated).Downing et al. concluded that this plasma level
of thedrugdidnotcausesigniﬁcantchanges inheart rate
or blood pressure, but elicited a well-deﬁned uterus-
relaxing effect.We found that the treatment with nifed-
ipine alone started on pregnancy day 16 was more
effective in delaying delivery than salmeterol treatment
alone (in the earlier study) (2).Similarly, thenifedipine–
salmeterol combination also had a greater effect than
the salmeterol–gestagen combination (2).
The short-term effects of nifedipine and its com-
bination with salmeterol were also tested in our
experiments. Nifedipine treatment started on day
18 did not delay labor, but the nifedipine–salmeterol
combination was as effective as the combination
started on the pregnancy day 16. The ability of nifed-
ipine to delay labor was tripled by its combination
with the b2-agonist.
In vivo progesterone pretreatment was earlier dem-
onstrated to worsen the relaxing effect of nifedipine
in vitro (9). Progesterone pretreatment also abolished
the ability of nifedipine to delay labor in hormone-
induced preterm delivery in rats in vivo. These results
correlate with the hypothesis that progesterone
decreases the activity of the L-type Ca2+ channels (10).
In previous study (9), we demonstrated synergism
in the uterus-relaxing effects of nifedipine and the b2-
agonist terbutaline in the isolated rat myometrium,
although the extent of the potentiation depended
on the sequence of administration of the two com-
pounds. When terbutaline was added ﬁrst in a single
dose, synergism was observed in EC50, but the Emax
of nifedipine was lower. When nifedipine was admin-
istered ﬁrst, the relaxing effect of terbutaline was
obviously stronger. The entry of Ca2+ into the cells
through the voltage-gated Ca2+ channels is one of the
crucial factors in the generation of smooth muscle
contraction. b2-Agonists activate the L-type Ca2+
channels and decrease the Emax of nifedipine. In
the opposite case, when nifedipine is administered
ﬁrst, the L-type Ca2+ channels are blocked; hence,
terbutaline cannot activate them.
However, our results contrast with the ﬁndings of
Downing and Hollingsworth (14). They found that
nifedipine displayed more potent myometrial inhibi-
tory effects in pseudopregnant rats treated with high
doses of progesterone than in non-pregnant rats. Our
results conﬁrmed the reduced uterus-relaxing effect
of nifedipine followed by gestagen treatment both in
vitro and in vivo; hence, we suppose that the discrep-
ancy in the quality of nifedipine–progesterone inter-
action might be explained by the dissimilarity of
experimental animals (pseudo- and non-pregnant
rats vs. pregnant rats).
Synergism between nifedipine and the b2-agonist
terbutaline was also investigated on human myome-
trium tissue, which revealed that both nifedipine and
terbutaline inhibit the oxytocin-induced myometrial
contractions dose-dependently. When terbutaline was
added ﬁrst, it decreased the EC50 of nifedipine (the
nifedipine curve was shifted to the right), although it
did not alter the Emax of nifedipine. In the opposite
case, nifedipine administered ﬁrst increased the relax-
ing effect of terbutaline even in very low concentra-
tion, although there was no difference in EC50. The
results suggest a parallelism between the human
situation and that in the rat myometrium.
The question arises as to whether the drug
interactions observed between nifedipine and the
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Figure 4. The effects of treatment with the nifedipine–terbutaline
combination on oxytocin-evoked human myometrial contractions
in vitro. A: (&) nifedipine (1011–105M); (.) terbutaline (107M) +
nifedipine (1011–105 M). B: (&) terbutaline (1011–105 M);
(.) nifedipine (107 M) + terbutaline (1011–105 M). *p < 0.05;
**p < 0.01.
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b2-adrenergic receptor agonists in vitro apply under
in vivo circumstances. In our in vivo study, two
osmotic pumps were implanted subcutaneously in
the rat and the administration of the two agents
was simultaneous and continuous. The results sug-
gested that the parallel administration of the two
compounds may lead to a similar beneﬁt as that of
nifedipine-potentiated terbutaline treatment.
A weakness of this study is that the experiments
do not provide data relating to the prompt effect of
the drugs in the onset of hormone-induced preterm
birth, but the investigation of this effect is almost
impossible in rats. The ﬁrst visual sign of the onset
of labor is vaginal bleeding. From this time on, at most
only 10–15 minutes is available until the delivery of
the ﬁrst fetus. This short period is not sufﬁcient for the
absorption of drugs administered. On the other hand,
intravenous drug administration to delivering rats
would be very difﬁcult and might well cause severe
stress for the animal, altering the delivery process.
Despite this weakness, our study reports the ﬁrst
attempt to delay anti-gestagen–prostaglandin-induced
preterm birth in vivo with a Ca2+ antagonist or a Ca2+
antagonist–gestagen combination. Additionally, the
effects of Ca2+ antagonist–b2-agonist combinations
on the pregnant human myometrium were proved.
Conclusion
Progesterone pretreatment abolished the ability of
nifedipine to delay labor in hormone-induced preterm
delivery in rats. The effect of nifedipine in tocolytic
therapy might be intensiﬁed through combination
with b2-adrenergic agonists. However, the adminis-
tration of b2-adrenergic agonists cannot precede that
of nifedipine.
Acknowledgement
This work was supported by a Hungarian OTKA
Research Grant (K62707).
Declaration of interest: The authors report no
conﬂicts of interest. The authors alone are responsible
for the content and writing of the paper.
References
1. Kim A, Shim JY. Emerging tocolytics for maintenance therapy
of preterm labour: oxytocin antagonists and calcium channels
blockers. Br J Pharmacol. 2006;113(Suppl 3):113–15.
2. Gálik M, Gáspár R, Kolarovszki-Sipiczki Z, Falkay G. Gesta-
gen treatment enhances the tocolytic effect of salmeterol in
hormone-induced preterm labor in the rat in vivo. Am J Obstet
Gynaecol. 2008;198:319.e1–5.
3. Oei SG. Calcium channel blockers for tocolysis: a review of
their role and safety following reports of serious adverse
events. Eur J Obstet Gynaecol. 2006;126:137–45.
4. Longo M, Jain V, Vedernikov YP, Hankins GDV,
Garﬁeld RE, Saade GR. Effects of L-type Ca2+-channel
blockade, K+ATP-channel opening and nitric oxide on human
uterine contractility in relation to gestational age and labor.
Mol Hum Reprod. 2003;9:159–64.
5. Wray S, Jones K, Kupittayanant S, Li Y, Matthew A,
Monir-Bisthty E, et al. Calcium signaling and uterine con-
tractility. J Soc Gynecol Investig. 2003;10:252–64.
6. Kobayashi T, Yamada Y, Fukao M, Tsutsuura M, Tohse N.
Regulation of Cav1.2 current: interaction with intracellular
molecules. J Pharmacol Sci. 2007;103:347–53.
7. Kamp TJ, Hell JW. Regulation of cardiac L-type calcium
channels by protein kinase A and protein kinase C. Circ
Res. 2000;87:1095–102.
8. Thirstrup S, Nielsen-Kudsk F, Dahl F. In vitro studies on the
interactions of b2-adrenoreceptor agonists, methylxanthenes,
Ca2+-channel blockers, K+-channel openers and other airway
smooth muscle relaxants in isolated guinea-pig trachea. Eur J
Pharmacol. 1997;326:191–200.
9. Hajagos-Tóth J, Falkay G, Gáspár R. Modiﬁcation of the
effect of nifedipine in the pregnant rat myometrium: the
inﬂuence of progesterone and terbutaline. Life Sci. 2009;
85:568–72.
10. Helguera G, Olcese R, Song M, Toro L, Stefani E.
Tissue-speciﬁc regulation of Ca2+ channel protein expres-
sion by sex hormones. Biochim Biophys Acta. 2002;1569:
59–66.
11. Rechberger T, Abramson SR, Woessner JF Jr. Onapristone
and prostaglandin E2 induction of delivery in the rat in late
pregnancy: a model for the analysis of cervical softening. Am J
Obstet Gynecol. 1996;175:719–23.
12. Hernandez F, Peluffo MC, Bas D, Stouffer RL, Tesone M.
Local effects of the sphingosine 1-phosphate on prostaglandin
F2alpha-induced luteolysis in the pregnant rat. Mol Reprod
Dev. 2009;76(12):1153–64.
13. Farina M, Ribeiro ML, Weissmann C, Estevez A, Billi S,
Vercelli C, et al. Biosynthesis and catabolism of prostaglandin
F2alpha (PGF2alpha) are controlled by progesterone in the rat
uterus during pregnancy. J Steroid Biochem Mol Biol. 2004;
91(4–5):211–18.
14. Downing SJ, Hollingsworth M. Nifedipine kinetics in the
rat and relationship between its serum concentrations and
uterine and cardiovascular effects. Br J Pharmacol. 1998;95:
23–32.
Interaction between nifedipine and betamimetics 1289
